سوق علاج حظ الكبد - النمو والاتجاهات وتأثير COVID-19 والتوقعات (2023 - 2028)

Table of Contents

1. 1. INTRODUCTION

   1. 1.1 Study Assumptions

   2. 1.2 Scope of the Study

2. 2. RESEARCH METHODOLOGY

3. 3. EXECUTIVE SUMMARY

4. 4. MARKET DYNAMICS

   1. 4.1 Market Overview

   2. 4.2 Market Drivers

      1. 4.2.1 Increasing Incidence of Fascioliasis Infection in Humans and Cattle

      2. 4.2.2 Raising Awareness on Liver Fluke, Fascioliasis Infection Among the People by Government Organizations

      3. 4.2.3 Increasing Research and Development for Liver Fluke Treatment

   3. 4.3 Market Restraints

      1. 4.3.1 Requirement of Long Treatment Cycles for Liver Fluke Infection

   4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

5. 5. MARKET SEGMENTATION

   1. 5.1 By Drug Type

      1. 5.1.1 Albendazole

      2. 5.1.2 Praziquantel

      3. 5.1.3 Triclabendazole

      4. 5.1.4 Nitazoxanide

      5. 5.1.5 Other Drugs

   2. 5.2 By Application

      1. 5.2.1 Human

      2. 5.2.2 Cattle

      3. 5.2.3 Other Applications

   3. 5.3 Geography

      1. 5.3.1 North America

         1. 5.3.1.1 United States

         2. 5.3.1.2 Canada

         3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

         1. 5.3.2.1 Germany

         2. 5.3.2.2 United Kingdom

         3. 5.3.2.3 France

         4. 5.3.2.4 Italy

         5. 5.3.2.5 Spain

         6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

         1. 5.3.3.1 China

         2. 5.3.3.2 Japan

         3. 5.3.3.3 India

         4. 5.3.3.4 Australia

         5. 5.3.3.5 South Korea

         6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle East & Africa

         1. 5.3.4.1 GCC

         2. 5.3.4.2 South Africa

         3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

         1. 5.3.5.1 Brazil

         2. 5.3.5.2 Argentina

         3. 5.3.5.3 Rest of South America

6. 6. COMPETITIVE LANDSCAPE

   1. 6.1 Company Profiles

      1. 6.1.1 Novartis AG

      2. 6.1.2 GlaxoSmithKline Plc

      3. 6.1.3 Bayer AG (Bayer Animal Health)

      4. 6.1.4 Endo International Plc (Par Pharmaceutical)

      5. 6.1.5 Romark Laboratories LC

      6. 6.1.6 Zoetis Inc

      7. 6.1.7 Merck & Co. Inc

      8. 6.1.8 Lupin Pharmaceuticals Inc

      9. 6.1.9 Schering-Plough Corporation

   *List Not Exhaustive

7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS